NYSE - Nasdaq Real Time Price USD
Bausch Health Companies Inc. (BHC)
4.9850 +0.1850 (+3.85%)
At close: 4:00:01 PM EDT
4.9900 +0.0050 (+0.10%)
After hours: 4:01:26 PM EDT
Trade BHC on Coinbase
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreChart Range Bar
Loading chart for BHC
- Previous Close
4.8000 - Open
4.8300 - Bid 4.9600 x 600000
- Ask 4.9700 x 870000
- Day's Range
4.8150 - 5.0850 - 52 Week Range
4.5700 - 8.6900 - Volume
2,152,886 - Avg. Volume
1,769,600 - Market Cap (intraday)
1.862B - Beta (5Y Monthly) 0.41
- PE Ratio (TTM)
-- - EPS (TTM)
-3.2400 - Earnings Date (est.) Jul 29, 2026
- Forward Dividend & Yield --
- Ex-Dividend Date Nov 10, 2010
- 1y Target Est
7.40
Recent News
View More
Performance Overview
Trailing total returns as of 6/24/2026, which may include dividends or other distributions. Benchmark is S&P/TSX Composite index (^GSPTSE) .
YTD Return
BHC
28.68%
S&P/TSX Composite index (^GSPTSE)
9.01%
1-Year Return
BHC
19.60%
S&P/TSX Composite index (^GSPTSE)
30.01%
3-Year Return
BHC
30.67%
S&P/TSX Composite index (^GSPTSE)
78.88%
5-Year Return
BHC
83.22%
S&P/TSX Composite index (^GSPTSE)
71.83%
Earnings Trends
View MoreAnalyst Insights
View MoreStatistics
View MoreValuation Measures
As of 6/23/2026
Market Cap
1.80B
Enterprise Value
21.29B
Trailing P/E
13.31
Forward P/E
1.11
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.17
Price/Book (mrq)
--
Enterprise Value/Revenue
2.02
Enterprise Value/EBITDA
11.01
Financial Highlights
Profitability and Income Statement
Profit Margin
-11.47%
Return on Assets (ttm)
5.93%
Return on Equity (ttm)
--
Revenue (ttm)
10.53B
Net Income Avi to Common (ttm)
-1.21B
Diluted EPS (ttm)
-3.2400
Balance Sheet and Cash Flow
Total Cash (mrq)
1.3B
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
1.12B
Compare
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
4.9850
+3.85%
Mkt Cap 1.862B
Industry Drug Manufacturers—Specialty & Generic
23.96
+3.34%
Mkt Cap 11.964B
Industry Drug Manufacturers—Specialty & Generic
17.27
+3.66%
Mkt Cap 5.51B
Industry Drug Manufacturers—Specialty & Generic
34.22
+3.04%
Mkt Cap 39.847B
Industry Drug Manufacturers—Specialty & Generic
15.73
-0.73%
Mkt Cap 49.687B
Industry Drug Manufacturers—Specialty & Generic
14.65
+2.34%
Mkt Cap 12.195B
Industry Drug Manufacturers—Specialty & Generic
17.00
+3.85%
Mkt Cap 1.89B
Industry Drug Manufacturers—Specialty & Generic
23.96
+1.91%
Mkt Cap 942.776M
Industry Drug Manufacturers—Specialty & Generic
Company Insights
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected. Learn more
Dividend Score
The distribution of earnings a company pays back to its shareholders based off the company’s profits. Usually paid out on a quarterly basis in the form of cash or additional stocks.
Hiring Score
A company’s hiring trends in key indicators can indicate how well the company is doing in terms of growing the company and where they are currently prioritizing.
Insider Sentiment Score
Vicker’s Insider Sentiment provides insights into trades made by insiders. This can be used to gain valuable insights and as a reflection of the prospect of the company based on insider trading.
Research Reports
View MoreDropping Coverage of Bausch Health Companies
Formerly known as Valeant Pharmaceuticals, Bausch Health is a global specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the dermatology, gastrointestinal, and ophthalmology markets. The company reports revenue in five segments: Bausch+Lomb (45% of revenue), Salix Pharmaceuticals (24%), international pharma (14%), ortho dermatology (7%), and diversified products (10%). Bausch is the market leader in consumer visioncare in India and China and the fourth-largest visioncare company by sales in the United States.
Placing Both Bausch Entities Under Review Following Mixed Court Ruling on Xifaxan Patent Case
Formerly known as Valeant Pharmaceuticals, Bausch Health is a global specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the dermatology, gastrointestinal, and ophthalmology markets. The company reports revenue in five segments: Bausch+Lomb (45% of revenue), Salix Pharmaceuticals (24%), international pharma (14%), ortho dermatology (7%), and diversified products (10%). Bausch is the market leader in consumer visioncare in India and China and the fourth-largest visioncare company by sales in the United States.
RatingPrice TargetEnd of an Era as Papa Leaves Bausch's Board; Shares Still Trade Below FVE After 18% Gain
Formerly known as Valeant Pharmaceuticals, Bausch Health is a global specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the dermatology, gastrointestinal, and ophthalmology markets. The company reports revenue in five segments: Bausch+Lomb (45% of revenue), Salix Pharmaceuticals (24%), international pharma (14%), ortho dermatology (7%), and diversified products (10%). Bausch is the market leader in consumer visioncare in India and China and the fourth-largest visioncare company by sales in the United States.
RatingPrice TargetMorningstar | A Weekly Summary of Stock Ideas and Developments in the Companies We Cover
This edition features putting the Bausch & Lomb spinoff under our lens, the regulation of utility companies, wagering on Tabcorp, and International Flavors & Fragrances, BlackRock, and Fortinet.